Necroptosis in cancer: An angel or a demon?

Tumor Biology

Volumn 39, Issue 6, 2017, Pages

  Wang, Tianzhen ^a   Jin, Yinji ^a   Yang, Weiwei ^a   Zhang, Lei ^a   Jin, Xiaoming ^a   Liu, Xi ^b   He, Yan ^a   Li, Xiaobo ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b INNER MONGOLIA PEOPLE S HOSPITAL   (China)

Author keywords

Cancer progression; Chemotherapy; Metastasis; Proliferation

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE 8; CXCL1 CHEMOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; FLUOROURACIL; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 3; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNINDEXED DRUG; VASCULOTROPIN; AGFG1 PROTEIN, HUMAN; NUCLEOPORIN; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK3 PROTEIN, HUMAN; RNA BINDING PROTEIN;

BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL STRUCTURE; COLON CANCER; DOWN REGULATION; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; MALIGNANT NEOPLASM; METASTASIS POTENTIAL; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; APOPTOSIS; GENETICS; INFLAMMATION; METABOLISM; NECROSIS; NEOPLASM; PATHOLOGY;

APOPTOSIS; CELL PROLIFERATION; HUMANS; INFLAMMATION; NECROSIS; NEOPLASMS; NUCLEAR PORE COMPLEX PROTEINS; REACTIVE OXYGEN SPECIES; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; RNA-BINDING PROTEINS;

EID: 85024123256     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1177/1010428317711539     Document Type: Review

References (126)

1. Lockshin RA and Zakeri Z. Programmed cell death and apoptosis: origins of the theory. Nat Rev Mol Cell Biol 2001; 2: 545-550.
2. Wallach D, Kang TB and Kovalenko A. Concepts of tissue injury and cell death in inflammation: a historical perspective. Nat Rev Immunol 2014; 14: 51-59.
3. Wallach D, Kang TB, Dillon CP, et al. Programmed necrosis in inflammation: toward identification of the effector molecules. Science 2016; 352: aaf2154.
4. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, et al. Regulated necrosis: the expanding network of nonapoptotic cell death pathways. Nat Rev Mol Cell Biol 2014; 15: 135-147.
5. Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADPribose) polymerase-1-dependent cell death by apoptosisinducing factor. Science 2002; 297: 259-263.
6. Vaseva AV, Marchenko ND, Ji K, et al. P53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 2012; 149: 1536-1548.
7. Cookson BT and Brennan MA. Pro-inflammatory programmed cell death. Trends Microbiol 2001; 9: 113-114.
8. Gao M, Monian P, Quadri N, et al. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell 2015; 59: 298-308.
9. Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112-119.
10. Chan FK, Shisler J, Bixby JG, et al. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem 2003; 278: 51613-51621.
11. Han W, Li L, Qiu S, et al. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 2007; 6: 1641-1649.
12. Newton K and Manning G. Necroptosis and inflammation. Annu Rev Biochem 2016; 85: 743-763.
13. Long JS and Ryan KM. New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy. Oncogene 2012; 31: 5045-5060.
14. Laster SM, Wood JG and Gooding LR. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol 1988; 141: 2629-2634.
15. Vercammen D, Beyaert R, Denecker G, et al. Inhibition of caspases increases the sensitivity of l929 cells to necrosis mediated by tumor necrosis factor. J Exp Med 1998; 187: 1477-1485.
16. Kawahara A, Ohsawa Y, Matsumura H, et al. Caspaseindependent cell killing by Fas-associated protein with death domain. J Cell Biol 1998; 143: 1353-1360.
17. Holler N, Zaru R, Micheau O, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489-495.
18. Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313-321.
19. Cho YS, Challa S, Moquin D, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137: 1112-1123.
20. He S, Wang L, Miao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNFalpha. Cell 2009; 137: 1100-1111.
21. Zhang DW, Shao J, Lin J, et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009; 325: 332-336.
22. Sun L, Wang H, Wang Z, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012; 148: 213-227.
23. Vanlangenakker N, Vanden Berghe T and Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ 2012; 19: 75-86.
24. Bertrand MJ, Milutinovic S, Dickson KM, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
25. Hayden MS and Ghosh S. Regulation of NF-κB by TNF family cytokines. Semin Immunol 2014; 26: 253-266.
26. Dondelinger Y, Jouan-Lanhouet S, Divert T, et al. NF-κBindependent role of IKKα/IKKβ in preventing RIPK1 kinase-dependent apoptotic and necroptotic cell death during TNF signaling. Mol Cell 2015; 60: 63-76.
27. Moquin DM, McQuade T and Chan FK. CYLD deubiquitinates RIP1 in the TNFα-induced necrosome to facilitate kinase activation and programmed necrosis. PLoS One 2013; 8: e76841.
28. Wertz IE, O’Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 2004; 430: 694-699.
29. Feoktistova M, Geserick P, Kellert B, et al. cIAPs block ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 2011; 43: 449-463.
30. McComb S, Cheung HH, Korneluk RG, et al. cIAP1 and cIAP2 limit macrophage necroptosis by inhibiting RIP1 and RIP3 activation. Cell Death Differ 2012; 19: 1791-1801.
31. Micheau O and Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181-190.
32. Geserick P, Hupe M, Moulin M, et al. Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J Cell Biol 2009; 187: 1037-1054.
33. Oberst A, Dillon CP, Weinlich R, et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011; 471: 363-367.
34. Deng HJ, Sun K, Guo C, et al. Construction of hasmicroRNA-338-3p lentiviral vector and verification of its target gene. Nan Fang Yi Ke Da Xue Xue Bao 2012; 32: 1098-1104.
35. Wang H, Sun L, Su L, et al. Mixed lineage kinase domainlike protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell 2014; 54: 133-146.
36. Dondelinger Y, Declercq W, Montessuit S, et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep 2014; 7: 971-981.
37. Cai Z, Jitkaew S, Zhao J, et al. Plasma membrane translocation of trimerized MLKL protein is required for TNFinduced necroptosis. Nat Cell Biol 2014; 16: 55-65.
38. Chen X, Li W, Ren J, et al. Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. Cell Res 2014; 24: 105-121.
39. Xia B, Fang S, Chen X, et al. MLKL forms cation channels. Cell Res 2016; 26: 517-528.
40. Robinson N, McComb S, Mulligan R, et al. Type I interferon induces necroptosis in macrophages during infection with Salmonella enterica serovar Typhimurium. Nat Immunol 2012; 13: 954-962.
41. Christofferson DE, Li Y and Yuan J. Control of life-ordeath decisions by RIP1 kinase. Annu Rev Physiol 2014; 76: 129-150.
42. Draber P, Kupka S, Reichert M, et al. LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes. Cell Rep 2015; 13: 2258-2272.
43. He S, Liang Y, Shao F, et al. Toll-like receptors activate programmed necrosis in macrophages through a receptorinteracting kinase-3-mediated pathway. Proc Natl Acad Sci U S A 2011; 108: 20054-20059.
44. Kaiser WJ, Sridharan H, Huang C, et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem 2013; 288: 31268-31279.
45. Upton JW, Kaiser WJ and Mocarski ES. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 2012; 11: 290-297.
46. Orozco S, Yatim N, Werner MR, et al. RIPK1 both positively and negatively regulates RIPK3 oligomerization and necroptosis. Cell Death Differ 2014; 21: 1511-1521.
47. Vande Walle L, Wirawan E, Lamkanfi M, et al. The mitochondrial serine protease HtrA2/Omi cleaves RIP1 during apoptosis of Ba/F3 cells induced by growth factor withdrawal. Cell Res 2010; 20: 421-433.
48. Welz PS, Wullaert A, Vlantis K, et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 2011; 477: 330-334.
49. Hitomi J, Christofferson DE, Ng A, et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008; 135: 1311-1323.
50. Chen D, Yu J and Zhang L. Necroptosis: an alternative cell death program defending against cancer. Biochim Biophys Acta 2016; 1865: 228-236.
51. Ofengeim D and Yuan J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat Rev Mol Cell Biol 2013; 14: 727-736.
52. Scaffidi P, Misteli T and Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195.
53. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial damps cause inflammatory responses to injury. Nature 2010; 464: 104-107.
54. Kaczmarek A, Vandenabeele P and Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 2013; 38: 209-223.
55. Jouan-Lanhouet S, Riquet F, Duprez L, et al. Necroptosis, in vivo detection in experimental disease models. Semin Cell Dev Biol 2014; 35: 2-13.
56. McQuade T, Cho Y and Chan FK. Positive and negative phosphorylation regulates RIP1-and RIP3-induced programmed necrosis. Biochem J 2013; 456: 409-415.
57. Xie T, Peng W, Liu Y, et al. Structural basis of RIP1 inhibition by necrostatins. Structure 2013; 21: 493-499.
58. Li JX, Feng JM, Wang Y, et al. The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis 2014; 5: e1278.
59. Wallberg F, Tenev T and Meier P. Analysis of apoptosis and necroptosis by fluorescence-activated cell sorting. Cold Spring Harb Protoc 2016; 2016: pdb.prot087387.
60. Nugues AL, El Bouazzati H, Hetuin D, et al. RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavage. Cell Death Dis 2014; 5: e1384.
61. Hockendorf U, Yabal M, Herold T, et al. RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells. Cancer Cell 2016; 30: 75-91.
62. Moriwaki K, Bertin J, Gough PJ, et al. Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. Cell Death Dis 2015; 6: e1636.
63. Liu P, Xu B, Shen W, et al. Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. Leukemia 2012; 26: 1293-1300.
64. Koo GB, Morgan MJ, Lee DG, et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res 2015; 25: 707-725.
65. Bhattacharya S, Chalk AM, Ng AJ, et al. Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death. Oncogene 2016; 35: 5282-5294.
66. Colbert LE, Fisher SB, Hardy CW, et al. Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. Cancer 2013; 119: 3148-3155.
67. He L, Peng K, Liu Y, et al. Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients. Onco Targets Ther 2013; 6: 1539-1543.
68. Fulda S and Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012; 11: 109-124.
69. Fu Z, Deng B, Liao Y, et al. The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis. BMC Cancer 2013; 13: 580.
70. Philipp S, Sosna J and Adam D. Cancer and necroptosis: friend or foe? Cell Mol Life Sci 2016; 73: 2183-2193.
71. Buchheit CL, Rayavarapu RR and Schafer ZT. The regulation of cancer cell death and metabolism by extracellular matrix attachment. Semin Cell Dev Biol 2012; 23: 402-411.
72. Takemura R, Takaki H, Okada S, et al. Polyl:C-induced, TLR3/RIP3-dependent necroptosis backs up immune effector-mediated tumor elimination in vivo. Cancer Immunol Res 2015; 3: 902-914.
73. Schmidt SV, Seibert S, Walch-Ruckheim B, et al. RIPK3 expression in cervical cancer cells is required for PolylCinduced necroptosis, IL-1α release, and efficient paracrine dendritic cell activation. Oncotarget 2015; 6: 8635-8647.
74. Yatim N, Jusforgues-Saklani H, Orozco S, et al. RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8(+) T cells. Science 2015; 350: 328-334.
75. Kang YJ, Bang BR, Han KH, et al. Regulation of NKT cellmediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling. Nat Commun 2015; 6: 8371.
76. Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13: 714-726.
77. Xu Y, Lin Z, Zhao N, et al. Receptor interactive protein kinase 3 promotes cisplatin-triggered necrosis in apoptosisresistant esophageal squamous cell carcinoma cells. PLoS One 2014; 9: e100127.
78. Jang MS, Lee SJ, Kang NS, et al. Cooperative phosphorylation of FADD by Aur-A and Plk1 in response to taxol triggers both apoptotic and necrotic cell death. Cancer Res 2011; 71: 7207-7215.
79. Tenev T, Bianchi K, Darding M, et al. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 2011; 43: 432-448.
80. Brown MF, Leibowitz BJ, Chen D, et al. Loss of caspase-3 sensitizes colon cancer cells to genotoxic stress via RIP1-dependent necrosis. Cell Death Dis 2015; 6: e1729.
81. Wu J, Huang Z, Ren J, et al. MLKL knockout mice demonstrate the indispensable role of MLKL in necroptosis. Cell Res 2013; 23: 994-1006.
82. Dunai ZA, Imre G, Barna G, et al. Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells. PLoS One 2012; 7: e41945.
83. Fulda S. Therapeutic exploitation of necroptosis for cancer therapy. Semin Cell Dev Biol 2014; 35: 51-56.
84. Lipponen P. Apoptosis in breast cancer: relationship with other pathological parameters. Endocr Relat Cancer 1999; 6: 13-16.
85. Sinicrope FA, Hart J, Hsu HA, et al. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clin Cancer Res 1999; 5: 1793-1804.
86. Poincloux L, Durando X, Seitz JF, et al. Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. Surg Oncol 2009; 18: 357-365.
87. Callagy GM, Pharoah PD, Pinder SE, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006; 12: 2468-2475.
88. Dawson SJ, Makretsov N, Blows FM, et al. Bcl2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010; 103: 668-675.
89. Ali HR, Dawson SJ, Blows FM, et al. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol 2012; 226: 97-107.
90. Wang RA, Lu YY and Fan DM. Reasons for cancer metastasis: a holistic perspective. Mol Clin Oncol 2015; 3: 1199-1202.
91. Zhang Y, Ou Y, Yu D, et al. Clinicopathological study of centrally necrotizing carcinoma of the breast. BMC Cancer 2015; 15: 282.
92. Yang C, Davis JL, Zeng R, et al. Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Cancer Discov 2013; 3: 212-223.
93. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
94. Wang WQ, Liu L, Sun HC, et al. Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization. J Hematol Oncol 2012; 5: 69.
95. Wong PP, Demircioglu F, Ghazaly E, et al. Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell 2015; 27: 123-137.
96. Liu X, Zhou M, Mei L, et al. Key roles of necroptotic factors in promoting tumor growth. Oncotarget 2016; 7: 22219-22233.
97. Seifert L, Werba G, Tiwari S, et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincleinduced immune suppression. Nature 2016; 532: 245-249.
98. Strilic B, Yang L, Albarran-Juarez J, et al. Tumour-cellinduced endothelial cell necroptosis via death receptor 6 promotes metastasis. Nature 2016; 536: 215-218.
99. Korniluk A, Koper O, Kemona H, et al. From inflammation to cancer. Ir J Med Sci 2017; 186: 57-62.
100. Qian BZ and Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
101. Grivennikov SI, Greten FR and Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
102. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006; 441: 431-436.
103. Condeelis J and Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-266.
104. Wyckoff J, Wang W, Lin EY, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 2004; 64: 7022-7029.
105. Najjar M, Saleh D, Zelic M, et al. RIPK1 and RIPK3 kinases promote cell-death-independent inflammation by toll-like receptor 4. Immunity 2016; 45: 46-59.
106. Weinlich R, Oberst A, Beere HM, et al. Necroptosis in development, inflammation and disease. Nat Rev Mol Cell Biol 2017; 18: 127-136.
107. Wegner KW, Saleh D and Degterev A. Complex pathologic roles of RIPK1 and RIPK3: moving beyond necroptosis. Trends Pharmacol Sci 2017; 38: 202-225.
108. Dayal D, Martin SM, Limoli CL, et al. Hydrogen peroxide mediates the radiation-induced mutator phenotype in mammalian cells. Biochem J 2008; 413: 185-191.
109. Tyack PL, Calambokidis J, Friedlaender A, et al. Formal comment on Schorr GS, Falcone EA, Moretti DJ, Andrews RD (2014) First long-term behavioral records from Cuvier’s beaked whales (Ziphius cavirostris) reveal record-breaking dives. PLos ONE 9(3): e92633. doi:10.1371/journal. Pone.0092633. PLoS One 2015; 10: e0142287.
110. Loeb LA. A mutator phenotype in cancer. Cancer Res 2001; 61: 3230-3239.
111. Jackson AL and Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 2001; 477: 7-21.
112. Tafani M, Sansone L, Limana F, et al. The interplay of reactive oxygen species, hypoxia, inflammation, and sirtuins in cancer initiation and progression. Oxid Med Cell Longev 2016; 2016: 3907147.
113. Wang X, Son YO, Chang Q, et al. NADPH oxidase activation is required in reactive oxygen species generation and cell transformation induced by hexavalent chromium. Toxicol Sci 2011; 123: 399-410.
114. Gupta SC, Hevia D, Patchva S, et al. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 2012; 16: 1295-1322.
115. Liu SL, Lin X, Shi DY, et al. Reactive oxygen species stimulated human hepatoma cell proliferation via cross-talk between PI3-K/PKB and JNK signaling pathways. Arch Biochem Biophys 2002; 406: 173-182.
116. De Luca A, Sanna F, Sallese M, et al. Methionine sulfoxide reductase a down-regulation in human breast cancer cells results in a more aggressive phenotype. Proc Natl Acad Sci U S A 2010; 107: 18628-18633.
117. Ho BY, Wu YM, Chang KJ, et al. Dimerumic acid inhibits SW620 cell invasion by attenuating H2O2-mediated MMP-7 expression via JNK/C-Jun and ERK/C-Fos activation in an AP-1-dependent manner. Int J Biol Sci 2011; 7: 869-880.
118. Roessner A, Kuester D, Malfertheiner P, et al. Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol Res Pract 2008; 204: 511-524.
119. Woo CH, Eom YW, Yoo MH, et al. Tumor necrosis factor-alpha generates reactive oxygen species via a cytosolic phospholipase A2-linked cascade. J Biol Chem 2000; 275: 32357-32362.
120. Yu X, Deng Q, Li W, et al. Neoalbaconol induces cell death through necroptosis by regulating RIPK-dependent autocrine TNFalpha and ROS production. Oncotarget 2015; 6: 1995-2008.
121. Wang JS, Wu D, Huang DY, et al. TAK1 inhibition-induced RIP1-dependent apoptosis in murine macrophages relies on constitutive TNF-α signaling and ROS production. J Biomed Sci 2015; 22: 76.
122. LaRocca TJ, Sosunov SA, Shakerley NL, et al. Hyperglycemic conditions prime cells for RIP1-dependent necroptosis. J Biol Chem 2016; 291: 13753-13761.
123. Ma YM, Peng YM, Zhu QH, et al. Novel CHOP activator LGH00168 induces necroptosis in A549 human lung cancer cells via ROS-mediated ER stress and NF-κB inhibition. Acta Pharmacol Sin 2016; 37: 1381-1390.
124. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14: e218-228.
125. Wang RA, Li QL, Li ZS, et al. Apoptosis drives cancer cells proliferate and metastasize. J Cell Mol Med 2013; 17: 205-211.
126. Fidler IJ. Macrophages and metastasis—a biological approach to cancer therapy. Cancer Res 1985; 45: 4714-4726.